The results from this study showed that enhanced CXCR4 signaling is sufficient to drive ERα-positive breast cancers to a metastatic and endocrine-therapy-resistant phenotype via increases in MAPK signaling [70]. This evidence concerns the gene CXCR4 and breast carcinoma.